Top

European Journal of Clinical Microbiology & Infectious Diseases

Published in:

01-02-2021 | Amphotericin B | Original Article

Molecular epidemiology and antifungal susceptibilities of Cryptococcus species isolates from HIV and non-HIV patients in Southwest China

Authors: Si-Ying Wu, Mei Kang, Ya Liu, Zhi-Xing Chen, Yu-Ling Xiao, Chao He, Ying Ma

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 2/2021

Abstract

To investigated the molecular epidemiology and in vitro antifungal susceptibility of Cryptococcus isolates from West China Hospital from HIV and non-HIV patients between 2009 and 2015. A total of 132 C. neoformans and C. gattii were subjected to antifungal susceptibility testing by E-test method. Among the 132 isolates, 42 C. neoformans and C. gattii were analyzed by mating type and URA5-RFLP. A total of 113 C. neoformans and C. gattii were subjected to multi-locus sequence typing (MLST). MLST results revealed that ST5 was the major molecular type. The wild-type (WT) phenotype was seen in 91.5–100% of C. neoformans isolates for amphotericin B, 5-flucytosine, fluconazole, and voriconazole. However, 72.3% (94/130) of C. neoformans isolates were non-wild-type (non-WT) to itraconazole by E-test method. In the sixth study year, the geometric mean, MIC₅₀ and MIC₉₀ of fluconazole were the highest (P < 0.001). Among 132 patients. 52 were coinfected with HIV and 80 were HIV-negative. Isolates from HIV and non-HIV patients showed no differences in susceptibility to amphotericin B (P = 0.544), 5-flucytosine (P = 0.063), fluconazole (P = 0.570), voriconazole (P = 0.542), and itraconazole (P = 0.787). Our study showed that Cryptococcus in southwest China showed a low degree of genetic diversity. The increased MIC values of fluconazole are noted. Cryptococcus isolates from HIV and non-HIV patients have shown no differences in susceptibility to five antifungal agents.

Rajasingham R, Smith RM, Park BJ, Jarvis JN, Govender NP, Chiller TM, Denning DW, Loyse A, Boulware DR (2017) Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis. Lancet Infect Dis 17(8):873–881. https://doi.org/10.1016/s1473-3099(17)30243-8CrossRefPubMedPubMedCentral

Makadzange AT, McHugh G (2014) New approaches to the diagnosis and treatment of cryptococcal meningitis. Semin Neurol 34(1):47–60. https://doi.org/10.1055/s-0034-1372342CrossRefPubMed

Dou HT, Xu YC, Wang HZ, Li TS (2015) Molecular epidemiology of Cryptococcus neoformans and Cryptococcus gattii in China between 2007 and 2013 using multilocus sequence typing and the DiversiLab system. Eur J Clin Microbiol Infect Dis 34(4):753–762. https://doi.org/10.1007/s10096-014-2289-2CrossRefPubMed

Espinel-Ingroff A, Kidd SE (2015) Current trends in the prevalence of Cryptococcus gattii in the United States and Canada. Infect Drug Resist 8:89–97. https://doi.org/10.2147/idr.S57686CrossRefPubMedPubMedCentral

Cogliati M (2013) Global molecularepidemiology of Cryptococcus neoformans and Cryptococcus gattii: an atlas of the molecular types. Scientifica (Cairo) 2013:675213. https://doi.org/10.1155/2013/675213CrossRef

Meyer W, Aanensen DM, Boekhout T, Cogliati M, Diaz MR, Esposto MC, Fisher M, Gilgado F, Hagen F, Kaocharoen S, Litvintseva AP, Mitchell TG, Simwami SP, Trilles L, Viviani MA, Kwon-Chung J (2009) Consensus multi-locus sequence typing scheme for Cryptococcus neoformans and Cryptococcus gattii. Med Mycol 47(6):561–570. https://doi.org/10.1080/13693780902953886CrossRefPubMed

Hagen F, Khayhan K, Theelen B, Kolecka A, Polacheck I, Sionov E, Falk R, Parnmen S, Lumbsch HT, Boekhout T (2015) Recognition of seven species in the Cryptococcus gattii/Cryptococcus neoformans species complex. Fungal Genet Biol 78:16–48. https://doi.org/10.1016/j.fgb.2015.02.009CrossRefPubMed

Perfect JR, Dismukes WE, Dromer F, Goldman DL, Graybill JR, Hamill RJ, Harrison TS, Larsen RA, Lortholary O, Nguyen MH, Pappas PG, Powderly WG, Singh N, Sobel JD, Sorrell TC (2010) Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of America. Clin Infect Dis 50(3):291–322. https://doi.org/10.1086/649858CrossRefPubMed

Nussbaum JC, Jackson A, Namarika D, Phulusa J, Kenala J, Kanyemba C, Jarvis JN, Jaffar S, Hosseinipour MC, Kamwendo D, van der Horst CM, Harrison TS (2010) Combination flucytosine and high-dose fluconazole compared with fluconazole monotherapy for the treatment of cryptococcal meningitis: a randomized trial in Malawi. Clin Infect Dis 50(3):338–344. https://doi.org/10.1086/649861CrossRefPubMed

10.

Muzoora CK, Kabanda T, Ortu G, Ssentamu J, Hearn P, Mwesigye J, Longley N, Jarvis JN, Jaffar S, Harrison TS (2012) Short course amphotericin B with high dose fluconazole for HIV-associated cryptococcal meningitis. J Infect 64(1):76–81. https://doi.org/10.1016/j.jinf.2011.10.014CrossRefPubMed

11.

Chong HS, Dagg R, Malik R, Chen SR, Carter D (2010) In vitro susceptibility of the yeast pathogen Cryptococcus to fluconazole and other azoles varies with molecular genotype. J Clin Microbiol 48(11):4115–4120. https://doi.org/10.1128/jcm.01271-10CrossRefPubMedPubMedCentral

12.

Espinel-Ingroff A, Aller AI, Canton E, Castanon-Olivares LR, Chowdhary A, Cordoba S, Cuenca-Estrella M, Fothergill A, Fuller J, Govender N, Hagen F, Illnait-Zaragozi MT, Johnson E, Kidd S, Lass-Florl C, Lockhart SR, Martins MA, Meis JF, Melhem MSC, Ostrosky-Zeichner L, Pelaez T, Pfaller MA, Schell WA, St-Germain G, Trilles L, Turnidge J (2012) Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for fluconazole, itraconazole, posaconazole, and voriconazole. Antimicrob Agents Chemother 56(11):5898–5906. https://doi.org/10.1128/aac.01115-12CrossRefPubMedPubMedCentral

13.

Chen JH, Varma A, Diaz MR, Litvintseva AP, Wollenberg KK, Kwon-Chung KJ (2008) Cryptococcus neoformans strains and infection in apparently immunocompetent patients, China. Emerg Infect Dis 14(5):755–762. https://doi.org/10.3201/eid1405.071312CrossRefPubMedPubMedCentral

14.

Feng XB, Yao ZR, Ren DM, Liao WQ, Wu JS (2008) Genotype and mating type analysis of Cryptococcus neoformans and Cryptococcus gattii isolates from China that mainly originated from non-HIV-infected patients. FEMS Yeast Res 8(6):930–938. https://doi.org/10.1111/j.1567-1364.2008.00422.xCrossRefPubMed

15.

Liu Y, Kang M, Wu SY, Ma Y, Chen ZX, Xie Y, Tang JT (2017) Different characteristics of cryptococcal meningitis between HIV-infected and HIV-uninfected patients in the southwest of China. Med Mycol 55(3):255–261. https://doi.org/10.1093/mmy/myw075CrossRefPubMed

16.

Xiao M, Chen SCA, Kong FR, Fan X, Cheng JW, Hou X, Zhou ML, Wang H, Xu YC, China Hosp Invasive Fungal S (2018) Five-year China Hospital Invasive Fungal Surveillance Net (CHIF-NET) study of invasive fungal infections caused by noncandidal yeasts: species distribution and azole susceptibility. Infect Drug Resist 11:1659–1667. https://doi.org/10.2147/idr.S173805CrossRefPubMedPubMedCentral

17.

Wu SY, Lei Y, Kang M, Xiao YL, Chen ZX (2015) Molecular characterisation of clinical Cryptococcus neoformans and Cryptococcus gattii isolates from Sichuan province, China. Mycoses 58(5):280–287. https://doi.org/10.1111/myc.12312CrossRefPubMed

18.

Zhu H, Qu F, Zhu LH (1993) Isolation of genomic DNAs from plants, fungi and bacteria using benzyl chloride. Nucleic Acids Res 21(22):5279–5280. https://doi.org/10.1093/nar/21.22.5279CrossRefPubMedPubMedCentral

19.

Chaturvedi S, Rodeghier B, Fan JJ, McClelland CM, Wickes BL, Chaturvedi V (2000) Direct PCR of Cryptococcus neoformans MAT alpha and MATa pheromones to determine mating type, ploidy, and variety: a tool for epidemiological and molecular pathogenesis studies. J Clin Microbiol 38(5):2007–2009. https://doi.org/10.1128/jcm.38.5.2007-2009.2000CrossRefPubMedPubMedCentral

20.

Meyer W, Castaneda A, Jackson S, Huynh M, Castaneda E, IberoAmerican Cryptococcal S (2003) Molecular typing of IberoAmerican Cryptococcus neoformans isolates. Emerg Infect Dis 9(2):189–195. https://doi.org/10.3201/eid0902.020246CrossRefPubMedPubMedCentral

21.

Clinical and Laboratory Standards Institute (2018) CLSI document M59. Epidemiological cutoff values for antifungal susceptibility testing, 2nd edn. CLSI, Wayne

22.

Kwon-Chung KJ, Fraser JA, Doering TL, Wang ZA, Janbon G, Idnurm A, Bahn YS (2014) Cryptococcus neoformans and Cryptococcus gattii, the etiologic agents of cryptococcosis. Cold Spring Harb Perspect Med 4(7). https://doi.org/10.1101/cshperspect.a019760

23.

Park SH, Choi SC, Lee KW, Kim MN, Hwang SM (2015) Genotypes of clinical and environmental isolates of Cryptococcus neoformans and Cryptococcus gattii in Korea. Mycobiology 43(3):360–365. https://doi.org/10.5941/myco.2015.43.3.360CrossRefPubMedPubMedCentral

24.

Worasilchai N, Tangwattanachuleeporn M, Meesilpavikkai K, Folba C, Kangogo M, Gross U, Weig M, Bader O, Chindamporn A (2017) Diversity and antifungal drug susceptibility of Cryptococcus isolates in Thailand. Med Mycol 55(6):680–685. https://doi.org/10.1093/mmy/myw130CrossRefPubMed

25.

Khayhan K, Hagen F, Pan WH, Simwami S, Fisher MC, Wahyuningsih R, Chakrabarti A, Chowdhary A, Ikeda R, Taj-Aldeen SJ, Khan Z, Ip M, Imran D, Sjam R, Sriburee P, Liao WQ, Chaicumpar K, Vuddhakul V, Meyer W, Trilles L, van Iersel LJJ, Meis JF, Klaassen CHW, Boekhout T (2013) Geographically structured populations of Cryptococcus neoformans variety grubii in Asia correlate with HIV status and show a clonal population structure. PLoS One 8(9). https://doi.org/10.1371/journal.pone.0072222

26.

Day JN, Qihui S, Thanh LT, Trieu PH, Van AD, Thu NH, Chau TTH, Lan NPH, Chau NVV, Ashton PM, Thwaites GE, Boni MF, Wolbers M, Nagarajan N, Tan PBO, Baker S (2017) Comparative genomics of Cryptococcus neoformans var. grubii associated with meningitis in HIV infected and uninfected patients in Vietnam. PLoS Negl Trop Dis 11(6). https://doi.org/10.1371/journal.pntd.0005628

27.

Chen SCA, Meyer W, Sorrell TC (2014) Cryptococcus gattii infections. Clin Microbiol Rev 27(4):980–1024. https://doi.org/10.1128/cmr.00126-13CrossRefPubMedPubMedCentral

28.

Fan X, Xiao M, Chen S, Kong F, Dou HT, Wang H, Xiao YL, Kang M, Sun ZY, Hu ZD, Wan Z, Chen SL, Liao K, Chu YZ, Hu TS, Zou GL, Hou X, Zhang L, Zhao YP, Xu YC, Liu ZY (2016) Predominance of Cryptococcus neoformans var. grubii multilocus sequence type 5 and emergence of isolates with non-wild-type minimum inhibitory concentrations to fluconazole: a multi-centre study in China. Clin Microbiol Infect 22(10). https://doi.org/10.1016/j.cmi.2016.07.008

29.

Hagen F, Colom MF, Swinne D, Tintelnot K, Latta R, Montagna MT, Torres-Rodriguez JM, Cogliati M, Velegraki A, Burggraaf A, Kamermans A, Sweere JM, Meis JF, Klaassen CHW, Boekhout T (2012) Autochthonous and dormant Cryptococcus gattii infections in Europe. Emerg Infect Dis 18(10):1618–1624. https://doi.org/10.3201/eid1810.120068CrossRefPubMedPubMedCentral

30.

Herkert PF, Meis JF, Salvador GLO, Gomes RR, Vicente VA, Muro MD, Pinheiro RL, Colombo AL, Schwarzbold AV, Oliveira CS, Ferreira MS, Queiroz-Telles F, Hagen F (2018) Molecular characterization and antifungal susceptibility testing of Cryptococcus neoformans sensu stricto from southern Brazil. J Med Microbiol 67(4):560–569. https://doi.org/10.1099/jmm.0.000698CrossRefPubMed

31.

Lee GHA, Arthur I, Merritt A, Leung M (2019) Molecular types of Cryptococcus neoformans and Cryptococcus gattii in Western Australia and correlation with antifungal susceptibility. Med Mycol 57(8):1004–1010. https://doi.org/10.1093/mmy/myy161CrossRefPubMed

32.

Smith KD, Achan B, Hullsiek KH, McDonald TR, Okagaki LH, Alhadab AA, Akampurira A, Rhein JR, Meya DB, Boulware DR, Nielsen K, Team A-CC (2015) Increased antifungal drug resistance in clinical isolates of Cryptococcus neoformans in Uganda. Antimicrob Agents Chemother 59(12):7197–7204. https://doi.org/10.1128/aac.01299-15CrossRefPubMedPubMedCentral

33.

Chen YC, Chang TY, Liu JW, Chen FJ, Chien CC, Lee CH, Lu CH (2015) Increasing trend of fluconazole-non-susceptible Cryptococcus neoformans in patients with invasive cryptococcosis: a 12-year longitudinal study. BMC Infect Dis 15(1). https://doi.org/10.1186/s12879-015-1023-8

34.

Nascimento E, Vitali LH, Kress MRV, Martinez R (2017) Cryptococcus neoformans and C gattii isolates from both HIV-infected and uninfected patients: antifungal susceptibility and outcome of cryptococcal disease. Rev Inst Med Trop Sao Paulo 59. https://doi.org/10.1590/s1678-9946201759049

35.

Lockhart SR, Iqbal N, Bolden CB, DeBess EE, Marsden-Haug N, Worhle R, Thakur R, Harris JR, Cryptococcus Gattii PNWP (2012) Epidemiologic cutoff values for triazole drugs in Cryptococcus gattii: correlation of molecular type and in vitro susceptibility. Diagn Microbiol Infect Dis 73(2):144–148. https://doi.org/10.1016/j.diagmicrobio.2012.02.018CrossRefPubMed

36.

Li M, Liao Y, Chen M, Pan WH, Weng LX (2012) Antifungal susceptibilities of Cryptococcus species complex isolates from AIDS and non-AIDS patients in Southeast China. Braz J Infect Dis 16(2):175–179. https://doi.org/10.1590/s1413-86702012000200012CrossRefPubMed

37.

Arsenijevic VA, Pekmezovic MG, Meis JF, Hagen F (2014) Molecular epidemiology and antifungal susceptibility of Serbian Cryptococcus neoformans isolates. Mycoses 57(6):380–387. https://doi.org/10.1111/myc.12171CrossRef

38.

Pan WH, Khayhan K, Hagen F, Wahyuningsih R, Chakrabarti A, Chowdhary A, Ikeda R, Taj-Aldeen SJ, Khan Z, Imran D, Sjam R, Sriburee P, Liao WQ, Chaicumpar K, Ingviya N, Mouton JW, Curfs-Breuker I, Boekhout T, Meis JF, Klaassen CHW (2012) Resistance of Asian Cryptococcus neoformans serotype A is confined to few microsatellite genotypes. PLoS One 7(3). https://doi.org/10.1371/journal.pone.0032868

Title: Molecular epidemiology and antifungal susceptibilities of Cryptococcus species isolates from HIV and non-HIV patients in Southwest China
Authors: Si-Ying Wu
Mei Kang
Ya Liu
Zhi-Xing Chen
Yu-Ling Xiao
Chao He
Ying Ma
Publication date: 01-02-2021
Publisher: Springer Berlin Heidelberg
Keywords: Amphotericin B
Itraconazole
Fluconazole
Voriconazole
Flucytosine
Human Immunodeficiency Virus
Published in: European Journal of Clinical Microbiology & Infectious Diseases / Issue 2/2021
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI: https://doi.org/10.1007/s10096-020-04013-4

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Molecular epidemiology and antifungal susceptibilities of Cryptococcus species isolates from HIV and non-HIV patients in Southwest China

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2021

A 2-step algorithm combining glutamate dehydrogenase and nucleic acid amplification tests for the detection of Clostridioides difficile in stool specimens

Gastrointestinal symptoms and the acquisition of enteric pathogens in Hajj pilgrims: a 3-year prospective cohort study

Evaluation of three commercial assays for SARS-CoV-2 molecular detection in upper respiratory tract samples

Treatment of community-acquired bacterial brain abscess: a survey among infectious diseases specialists in France, Sweden, Australia, and Denmark

Rapid detection of carbapenemase-producing organisms directly from blood cultures positive for Gram-negative bacilli

Clinical and molecular epidemiology of vancomycin-resistant Enterococcus faecium bacteremia from an Indian tertiary hospital

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page